Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

Rapamycin (Sirolimus)化学構造

分子量(MW):914.18

Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。

サイズ 価格 在庫  
JPY 44060.32 あり
JPY 10079.16 あり
JPY 38876.76 あり
JPY 96471.96 あり

文献中の引用(63)

カスタマーフィードバック(12)

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。
ターゲット
mTOR [1]
(HEK293 cells)
~0.1 nM
体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MkPwR5l1d3SxeHnjJGF{e2G7 MorONVAhdk1? M{C3cVczKGh? MV\EUXNQ MXTQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= NX;mSplqOjR7MEC4O|M>
HT-29 MmLYR5l1d3SxeHnjJGF{e2G7 NV;DcJdkOTBibl2= NInBW3U4OiCq NUf1bVVsTE2VTx?= MWrQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? MYSyOFkxODh5Mx?=
HT-29 NF34[m1EgXSxdH;4bYMhSXO|YYm= NWLEW5R3OTBibl2= MVu3NkBp Ml32SG1UVw>? NVnGTlQxWG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? M12zWFI1QTByOEez
PC3 MorYT4lv[XOnIFHzd4F6 M4noPFExOCCwTR?= MXSxJIg> MXHEUXNQ MYHQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= NHjkXZQzOTl5OE[4Ny=>
PC3 NWX1cZpkU2mwYYPlJGF{e2G7 Mo\JNVAxKG6P NFjrOYoyKGh? MoW0SG1UVw>? MojoSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MUiyNVk4QDZ6Mx?=
PC3 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLYNU42KM7:TR?= M4D1[FEhcA>? NH\Vc2lFVVOR MWnJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? MlHWNlE6Pzh4OEO=
HEK293 NEHpTYFHfW6ldHnvckBCe3OjeR?= MmDSNVAxKG6P NFizeJk5KGh? NVTEUIN[TE2VTx?= MlnMTY5pcWKrdIOgWHBCNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gVIRk\DRid3n0bEBGSzVyIH;mJFUxKG6P MWKyNVU{QTNyMR?=
BT-20 NX:xSG9sU2mwYYPlJGF{e2G7 NH;zTYQzOCEQvF2= Mn[xSG1UVw>? MXTEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? M3W3XFIyOzV|NUWx
U937 MlLlRY51cWKjY4TldolidCCDc4PhfS=> NETpXIQ2OCEQvF2= M374VVQ5KGh? M1nYfGROW09? MornTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| MX2yNVE1OjFyNh?=
U937 MkDaRY51cWKjY4TldolidCCDc4PhfS=> M1fyZ|UxKM7:TR?= NWLG[oVDPDhiaB?= M3fjWGROW09? M3TUdWRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ|Mj2yJIlvKFV7M{egZ4VtdHN? MX2yNVE1OjFyNh?=
U937 MoLiRY51cWKjY4TldolidCCDc4PhfS=> MX61NEDPxE1? NXHxOWczPDhiaB?= NF3RUGdFVVOR NVXLeHJNTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? MkDpNlEyPDJzME[=
MCF-7 M1;5cGF2fG:yaHHnfUBCe3OjeR?= NX;PdZFQOzBibl2= M{H3R|QhcA>? MojDSG1UVw>? M{Xsc2lv\HWlZYOgZZV1d3CqYXf5 MlzJNlAxOjhzM{S=
U87MG M{\LbmtqdmG|ZTDBd5NigQ>? MoH4NUDPxE1? MnXoOkBp NEfCclRFVVOR MkD2VI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? NY\FNJdJOTl6NEi0NFQ>
U87MG M{DXWmtqdmG|ZTDBd5NigQ>? NInxfI0yKM7:TR?= NHzrd3A3KGh? Mm\DSG1UVw>? MV;Qc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= M{f4VlE6QDR6NEC0
U87MG MoLIT4lv[XOnIFHzd4F6 M3fUflEh|ryP NYHLZms{PiCq MWnEUXNQ NGHqRWtFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= NGfXeHMyQTh2OESwOC=>
U87MG MoLTT4lv[XOnIFHzd4F6 MnjKNUDPxE1? NF7iSpc3KGh? NU\Ze5JYTE2VTx?= NYXufVRyTG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w NV;pbGEyOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb MYrBeZRweGijZ4mgRZN{[Xl? NGnQPY4xNjJizszN MkDRNlQhcA>? NFTWVYNFVVOR NX35WmNYUW6mdXPld{BifXSxcHjh[5k> MkfqNVg{QTF7NEm=
COS7 cells expressing EGFP-LC3 M3vhfGF2fG:yaHHnfUBCe3OjeR?= MXqwMlIh|ryP MorXNlQhcA>? M134Z2ROW09? NED6fmVKdmS3Y3XzJIF2fG:yaHHnfS=> NInISVUyQDN7MUm0PS=>
H4 MVXGeY5kfGmxbjDBd5NigQ>? MW[wMlIh|ryP M{LlZlI1KGh? MlezSG1UVw>? M2CzTmlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> M37M[|E5ODJ2NUi0
HeLa MX3GeY5kfGmxbjDBd5NigQ>? M{e0XVExOCCwTR?= MUKzOkBp M{\qVmROW09? NHHBZW1KdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MkfPNVc2PjN|OEW=
HeLa NVHTNlN7TnWwY4Tpc44hSXO|YYm= NF;N[mUyODBibl2= MlLYN|YhcA>? NEHrWFFFVVOR MnLzTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v NHjJUFIyPzV4M{O4OS=>
HeLa MlXISpVv[3Srb36gRZN{[Xl? M3fER|ExOCCwTR?= MYKzOkBp M1LUVWROW09? MX\JcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= NFrZRooyPzV4M{O4OS=>
SYF M1;LVWZ2dmO2aX;uJGF{e2G7 M1XkXlExOCCwTR?= NFf6UG8zPCCq M2XubWROW09? M2LJZWlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> M2\BRVE4PTZ|M{i1
SYF MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZd|ExOCCwTR?= NYDm[IJVOjRiaB?= MkfwSG1UVw>? MoLtTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= NXzKTo1VOTd3NkOzPFU>
HEK293T M2nQc2FvfGm4aYLhcEBCe3OjeR?= NYDkZYdxOSCwTR?= Mn[3OEBl NHKzfXlFVVOR M4\FNmlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N NILJSm0yPzR6NUWwNS=>
HEK293T MmPyRY51cX[rcnHsJGF{e2G7 MU[xJI5O MYC0JIQ> M1vjemROW09? M1K2TWlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N NWrFTlJGOTd2OEW1NFE>
PBMC M{fUNmZ2dmO2aX;uJGF{e2G7 NGr2SVkyKG6P NVTFRXlZOTRiZB?= MWHEUXNQ MoW2VoVlfWOnczDDR3I2KGSnboPpeJk> NE\nVlAyPzR6NUWwNS=>
PBMC MWjGeY5kfGmxbjDBd5NigQ>? MX:xJI5O M2rYXlE1KGR? M3q3fWROW09? NXjSO|ZrTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? M4DqVlE4PDh3NUCx
HEK293 cells MYnLbY5ie2ViQYPzZZk> NX3kd5B[PTBibl2= MVe0OUBucW5? NInwb2JFVVOR NGnsboNKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P MlHnNVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc M1TwfWZ2dmO2aX;uJGF{e2G7 NX3USpBmOTByIH7N NFHUeIo1KGh? MkHGSG1UVw>? NUHzeIpHUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? NIPFe2syPzF{OEK2Ni=>
Human mixed lymphocyte NH3Te2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL6N5hsPSCwTR?= MYDEUXNQ M4DXZmlEPTB;MT62JI5ONg>? NUK4S4VZOTZzOEW4OlU>
Lewis rat lymph node cells MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK5OUDPxE1? M1HqRWROW09? M4XDfWlEPTB;Mj62JO69VQ>? NUXkdWM6OTZzOEW4OlU>
cells from the thymus of normal BALB/c mice NH\WeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSxNEBvVQ>? NWHiSINyPzJiaB?= NXPZSGZ7TE2VTx?= MkP3TY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?= MlT3NVAxOjF7NEi=
MRK-nu-1 NIH3S5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvHTWM2OD1yLki0OUBxVQ>? MlfDV2FPT0WU
OCUB-M M{Xl[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDQS5RKSzVyPUWuNlQheE1? MXnTRW5ITVJ?
SF539 NY\GXIJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\zXlhKSzVyPUGxMlYheE1? NFPNXWdUSU6JRWK=
ES4 NX\rS|NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\mS2lEPTB;MkGuOUBxVQ>? M1rUOXNCVkeHUh?=
RL95-2 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH0VI5KSzVyPUGwO{BxVQ>? MoW3V2FPT0WU
LC-2-ad NGC3RWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInscXNKSzVyPUSyN{BxVQ>? NUnmOph1W0GQR1XS
Daudi MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzuTWM2OD12M{SgdG0> MlrqV2FPT0WU
NTERA-S-cl-D1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPxWFdKSzVyPUS0N{BxVQ>? MmDSV2FPT0WU
OS-RC-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\JcItKSzVyPU[1NkBxVQ>? MV3TRW5ITVJ?
VA-ES-BJ M2nJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17GUmlEPTB;N{KzJJBO MkPEV2FPT0WU
GR-ST MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfqS3BUUUN3ME24OFYheE1? MYTTRW5ITVJ?
SW872 NEXMdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7VbWxJUUN3ME24OFYheE1? NVT1VZNnW0GQR1XS
NOS-1 NHro[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17DeGlEPTB;OEexJJBO MVfTRW5ITVJ?
MC116 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;GRmlEPTB;OUi1JJBO MmX4V2FPT0WU
NCI-H1355 NHvMdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XNWGlEPTB;MT6wNUBvVQ>? MXXTRW5ITVJ?
RPMI-8226 MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTRW5d7UUN3ME2xMlE6KG6P NEW3[GNUSU6JRWK=
TE-15 NHLtbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwM{[gcm0> NH\NepJUSU6JRWK=
Ramos-2G6-4C10 NULKOGxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LtWWlEPTB;MT60OkBvVQ>? NHK0bWFUSU6JRWK=
KU812 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrGTWM2OD1{LkCxJI5O NWHlUmJ6W0GQR1XS
EW-1 NIqwRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD1TWM2OD1{LkG3JI5O Mnz0V2FPT0WU
KS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjPZVdtUUN3ME2yMlQ2KG6P MWDTRW5ITVJ?
SK-LMS-1 NXvtdFAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe5c3FKSzVyPUKuOFkhdk1? MY\TRW5ITVJ?
TGBC1TKB NHTtcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTQTWM2OD1{Lk[5JI5O NVX5bmJ[W0GQR1XS
TE-6 NIm2NHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLZTWM2OD1{Lke3JI5O MYXTRW5ITVJ?
ETK-1 NX;PVplCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJwOEKgcm0> M1zMVnNCVkeHUh?=
BE-13 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W5SmlEPTB;Mj65PUBvVQ>? M3PuOnNCVkeHUh?=
A3-KAW NInMNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:5[lQxUUN3ME2yMlk6KG6P M37ZTnNCVkeHUh?=
TE-10 NEP3UWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNwMzDuUS=> MWrTRW5ITVJ?
DOHH-2 Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;UTWM2OD1|LkO1JI5O NIG1b4NUSU6JRWK=
ES6 NWOzO3o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwNEOgcm0> NUXy[nFSW0GQR1XS
OPM-2 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTRwMUWgcm0> MVXTRW5ITVJ?
SH-4 MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zab2lEPTB;ND6zOEBvVQ>? MUTTRW5ITVJ?
NB13 MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG4c4pJUUN3ME20MlM3KG6P M{O3ZnNCVkeHUh?=
HUTU-80 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nBXGlEPTB;ND60NkBvVQ>? NYTtN5VOW0GQR1XS
CCRF-CEM M4nTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTRwOUSgcm0> NInqcVRUSU6JRWK=
TGBC24TKB MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjIc2Z1UUN3ME21MlUyKG6P NVPmd2JnW0GQR1XS
697 NFnS[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7mTWM2OD14LkK4JI5O MXnTRW5ITVJ?
J-RT3-T3-5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHENXJKSzVyPU[uOFYhdk1? MmjXV2FPT0WU
KALS-1 NG\mUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTZwNU[gcm0> NWDuWXM3W0GQR1XS
no-10 NWjmTIFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXFSZlKSzVyPUeuNlkhdk1? NWPCOmVZW0GQR1XS
SK-NEP-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTkTWM2OD16Lke5JI5O MlTaV2FPT0WU
L-540 M3HnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFyLkSyJI5O MXnTRW5ITVJ?
JiyoyeP-2003 M4H6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFyLkm0JI5O NHnCc4JUSU6JRWK=
HH MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj6Uo9KSzVyPUGxMlM6KG6P M4\qSXNCVkeHUh?=
SR NUS3UnlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:5[ZNKSzVyPUGxMlQ2KG6P MWTTRW5ITVJ?
QIMR-WIL Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDDVmVGUUN3ME2xNU45PSCwTR?= MX7TRW5ITVJ?
A4-Fuk NX\sRVFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWxTWM2OD1zMz6xNkBvVQ>? NUHQT|ZXW0GQR1XS
CESS MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF|LkGzJI5O MkXLV2FPT0WU
KE-37 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm4OY1KSzVyPUG2MlA4KG6P M3PzbHNCVkeHUh?=
SK-UT-1 NGDj[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\IfnRKSzVyPUG2MlgyKG6P M{fuXXNCVkeHUh?=
SIG-M5 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF5LkK1JI5O MmfsV2FPT0WU
HT MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i0bGlEPTB;MUeuOkBvVQ>? NWDJTWJNW0GQR1XS
DEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn2XYpKSzVyPUG3Mlk6KG6P MXTTRW5ITVJ?
SK-PN-DW M{nZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJyLkKzJI5O MXPTRW5ITVJ?
RPMI-8402 NHXu[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJzLke3JI5O Mn\1V2FPT0WU
RPMI-6666 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrUO2JKSzVyPUK0MlQzKG6P MWPTRW5ITVJ?
NCI-H720 NVjmVnY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ3LkSxJI5O MnnFV2FPT0WU
EW-16 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJ4Lki3JI5O NGPsSW9USU6JRWK=
BL-70 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr1PJpKSzVyPUK4MlM5KG6P NHnBSFNUSU6JRWK=
SF126 NFPuXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn5eYJKSzVyPUOwMlM5KG6P MVzTRW5ITVJ?
BC-1 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf3TWM2OD1|MT6yOkBvVQ>? NYfTPYNTW0GQR1XS
MHH-PREB-1 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K5fWlEPTB;M{KuOFQhdk1? NYWzc3ZMW0GQR1XS
A101D NW\Fb3RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK4TWM2OD1|Mj62NkBvVQ>? NX7sd41QW0GQR1XS
NMC-G1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfITWM2OD1|Mz62O{BvVQ>? MWrTRW5ITVJ?
LB1047-RCC NUX0bZo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzVTYtKSzVyPUO0MlY6KG6P MWPTRW5ITVJ?
EM-2 M{noN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nFWWlEPTB;M{iuOVMhdk1? M3HZT3NCVkeHUh?=
COLO-684 NG\JSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HEfWlEPTB;M{muPEBvVQ>? NIOxWVlUSU6JRWK=
Becker NH7tVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3qdGpJUUN3ME20NU4xPSCwTR?= NILCT3BUSU6JRWK=
BL-41 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTR|Lk[2JI5O M4jsdnNCVkeHUh?=
MDA-MB-134-VI NXXGR5BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHSV2FKSzVyPUS0MlAzKG6P NVTrNJpJW0GQR1XS
L-363 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDjd3lKSzVyPUS0Mlc{KG6P NIqwUY9USU6JRWK=
ECC4 M2P4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjLTWM2OD12ND63PEBvVQ>? NX35WItFW0GQR1XS
A388 NV21TYE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLoZmJ7UUN3ME20OE45OiCwTR?= M1vHdXNCVkeHUh?=
HEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;HO5pKSzVyPUS5Mlc6KG6P MmXPV2FPT0WU
RKO Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1riSWlEPTB;NUCuNlkhdk1? NW\uOJNJW0GQR1XS
KINGS-1 M2PUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTVzLkW1JI5O M3HjUHNCVkeHUh?=
EB-3 NY[zeVAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHVTnBKSzVyPUWyMlY4KG6P NIjWXmtUSU6JRWK=
ARH-77 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\0TWM2OD13Mj64JI5O NFLOepBUSU6JRWK=
GCIY Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Hh[2lEPTB;NUOuOFYhdk1? MWXTRW5ITVJ?
NCI-H1304 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLzU4xpUUN3ME21O{4zOiCwTR?= NE\6UoVUSU6JRWK=
KARPAS-299 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XFOGlEPTB;NkGuPFIhdk1? M3z3OnNCVkeHUh?=
IA-LM MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXUOYhKSzVyPU[4MlE{KG6P MkLGV2FPT0WU
GI-1 M1u5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTdyLkO5JI5O MmPCV2FPT0WU
TE-11 M2DrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTwZZlKSzVyPUe3MlE4KG6P M2TCNHNCVkeHUh?=
LS-411N NELDNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPCcIlKSzVyPUe3MlU4KG6P NWrvdXJKW0GQR1XS
no-11 M1TwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLSVXBwUUN3ME24N{4zPCCwTR?= M{DYV3NCVkeHUh?=
MV-4-11 NXnJ[2FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6yWYdKSzVyPUizMlc{KG6P NIfRTWpUSU6JRWK=
BV-173 NInyXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M360R2lEPTB;OEOuPVchdk1? MWjTRW5ITVJ?
CMK MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPOTWM2OD16ND6xOkBvVQ>? MUDTRW5ITVJ?
LC4-1 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTh4LkeyJI5O NIXBR29USU6JRWK=
COR-L279 NUX2VnJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDqTWc2UUN3ME24O{4zPSCwTR?= MYLTRW5ITVJ?
NCI-H209 M1u0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrJXWZKSzVyPUi3MlQyKG6P MljIV2FPT0WU
Raji MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HTcWlEPTB;OEmuO|Ihdk1? MkPNV2FPT0WU
LB996-RCC Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvSTWM2OD17Mz60N{BvVQ>? NF[3VZRUSU6JRWK=
NCI-H526 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTl|LkW5JI5O M2XjXXNCVkeHUh?=
KGN MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPCbIJKSzVyPUm2MlI6KG6P M3KwO3NCVkeHUh?=
MOLT-4 NX35fJY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nYSGlEPTB;OU[uO|khdk1? NGDIXVZUSU6JRWK=
PF-382 NVzPXJRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTl4Lke5JI5O NVP0UHhrW0GQR1XS
BC-3 M{nQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LhPWlEPTB;OUmuNVghdk1? M1vJZ3NCVkeHUh?=
KARPAS-422 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFyMj6wPUBvVQ>? MnSyV2FPT0WU
SBC-1 NEn4[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7kTWM2OD1zMEeuO|Uhdk1? MULTRW5ITVJ?
LC-1F MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf0NFNYUUN3ME2xNFgvODVibl2= M4HwcHNCVkeHUh?=
GB-1 NX7xTIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PrOmlEPTB;MUC5MlAzKG6P NFnBXYVUSU6JRWK=
SNB75 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnz[GNYUUN3ME2xNVkvPjlibl2= NGTLXJhUSU6JRWK=
BB65-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr4TWM2OD1zMUmuPVMhdk1? NVPFO3NDW0GQR1XS
NCI-N87 M3jJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF{MT65PEBvVQ>? MUPTRW5ITVJ?
IST-MEL1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7HN5lKSzVyPUGyNk4{QCCwTR?= MVfTRW5ITVJ?
HOP-62 M13Zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HjTWlEPTB;MUK2Mlg6KG6P NYqxN|BRW0GQR1XS
ACN NGW5blVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3qNXp3UUN3ME2xOFYvPzVibl2= NVHIfJJbW0GQR1XS
DMS-114 NGrWNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF3MD62O{BvVQ>? M2XNSHNCVkeHUh?=
MLMA NIfUPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;NbHlKSzVyPUG1PU45QCCwTR?= MoHwV2FPT0WU
HT-144 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\KSWlEPTB;MU[1MlQ{KG6P NVrafo5oW0GQR1XS
C2BBe1 M4HhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[0XWZKSzVyPUG2O{44PiCwTR?= M333cHNCVkeHUh?=
L-428 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHhUGN1UUN3ME2xO|cvPyCwTR?= NXnMbXZIW0GQR1XS
DU-4475 NFvPNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\ReZRKSzVyPUG4O{43QCCwTR?= MWLTRW5ITVJ?
CP67-MEL NYnTcIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF7OT6zPEBvVQ>? M4XseHNCVkeHUh?=
MEG-01 M3\rZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;XOmlEPTB;MkCxMlk3KG6P MYnTRW5ITVJ?
IST-SL2 M1\qcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:xXpNKSzVyPUKwPE43OyCwTR?= M1P4OHNCVkeHUh?=
ES8 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PFZWlEPTB;MkK1Mlk1KG6P MW\TRW5ITVJ?
COLO-800 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj0TWM2OD1{M{WuNlghdk1? NWHPTYNRW0GQR1XS
MFH-ino MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfhTWM2OD1{M{WuPFQhdk1? M{j0cXNCVkeHUh?=
OVCAR-4 NWK3b5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3jT|lKSzVyPUKzO{4zPCCwTR?= MYHTRW5ITVJ?
PSN1 NYryfpZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ2Mj63NUBvVQ>? NHLae2JUSU6JRWK=
EW-12 NUPjV4FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nVVGlEPTB;MkSzMlEhdk1? MYnTRW5ITVJ?
HCC1599 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ4MT60O{BvVQ>? MmH4V2FPT0WU
SJSA-1 M3;TVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uyO2lEPTB;MkexMlQ3KG6P NVzYUG9GW0GQR1XS
ST486 NH7ZUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqzTWM2OD1{OU[uNVQhdk1? NILOZ2xUSU6JRWK=
NOMO-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\BZVVpUUN3ME2zNFAvOjFibl2= MkXQV2FPT0WU
MN-60 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13OeWlEPTB;M{C1MlMzKG6P MoWyV2FPT0WU
HCC1187 NULFdmk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHteWlKSzVyPUOwO{4zPSCwTR?= NFPDSJFUSU6JRWK=
SW982 NX;HVYJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYntdHBzUUN3ME2zNVQvPzVibl2= NXLIUZBsW0GQR1XS
LB647-SCLC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPZTWM2OD1|MkiuO|Ehdk1? M1ThNXNCVkeHUh?=
HC-1 NY\5eFhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PQUmlEPTB;M{O1MlUhdk1? NWHQcVhHW0GQR1XS
EHEB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTN|Nz61NkBvVQ>? NIW3OodUSU6JRWK=
TUR NV\kSJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN4Mz65OUBvVQ>? M33iVnNCVkeHUh?=
LU-139 NEi1Z2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XTcGlEPTB;M{e4MlAzKG6P MnfCV2FPT0WU
NB1 Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3WeGZKSzVyPUO4OE41PSCwTR?= MXrTRW5ITVJ?
BB30-HNC MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TVXmlEPTB;M{i4MlMzKG6P NX\NdJJSW0GQR1XS
HAL-01 NVHrblROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN6OT6yOkBvVQ>? MkXzV2FPT0WU
K5 NF;SXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHvTWM2OD12MUGuN|chdk1? MlT0V2FPT0WU
MZ2-MEL NHT2PWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\KcnR5UUN3ME20NVMvPjRibl2= MWfTRW5ITVJ?
RXF393 NEjXUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTRzNj60OUBvVQ>? MV\TRW5ITVJ?
NCI-H1648 NEPRVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTqUZRKSzVyPUSxO{42OyCwTR?= MYPTRW5ITVJ?
TE-12 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTR|ND6yOkBvVQ>? MoXXV2FPT0WU
EoL-1- M2\sWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;PRWlEPTB;NEO3Mlk5KG6P NHX1WYpUSU6JRWK=
JAR NVzjNGpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nxe2lEPTB;NEO4MlYzKG6P NV3RSXQ4W0GQR1XS
DSH1 M2m0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWwbJpQUUN3ME20OVgvQTFibl2= MYPTRW5ITVJ?
NCI-H187 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rGZ2lEPTB;NE[yMlgyKG6P NGS5cpZUSU6JRWK=
HCE-4 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXGepZKSzVyPUS3O{43PiCwTR?= M4THdXNCVkeHUh?=
8-MG-BA NEjnSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW0[4VTUUN3ME21PFEvPTJibl2= NXTWeJFjW0GQR1XS
KLE M3PxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOwTWM2OD13OEWuNkBvVQ>? MoDTV2FPT0WU
KNS-42 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7VVnhoUUN3ME21PFYvQDFibl2= M2LGbXNCVkeHUh?=
MSTO-211H MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jhXmlEPTB;NkC5Mlc1KG6P M2rXNnNCVkeHUh?=
GDM-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S3eWlEPTB;NkG0MlA6KG6P MlXrV2FPT0WU
TE-1 NFfrSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHvfGFLUUN3ME22OFYvOTJibl2= MkO1V2FPT0WU
BT-474 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfOTWM2OD14NEeuNFYhdk1? MU\TRW5ITVJ?
KARPAS-45 NVXqSYlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTZ2Nz62JI5O MV;TRW5ITVJ?
MOLT-16 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTZ2Nz65N{BvVQ>? M1fCZXNCVkeHUh?=
KURAMOCHI MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n5OWlEPTB;NkW3MlUyKG6P MXzTRW5ITVJ?
K-562 NWnxUJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTZ4OT61NUBvVQ>? M4PYPHNCVkeHUh?=
EKVX MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jUXWlEPTB;NkeyMlcyKG6P NXLRWXRTW0GQR1XS
GAK NGHpN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfRTm57UUN3ME22O|UvOyCwTR?= MnuxV2FPT0WU
NCI-SNU-5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTZ7MD6wNUBvVQ>? NFXCPGZUSU6JRWK=
NCI-H2126 NGHvWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33DZWlEPTB;N{K2Mlg4KG6P NUfQVoQ2W0GQR1XS
CTV-1 NH[zPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PqTmlEPTB;N{S0Mlkhdk1? NITtOYFUSU6JRWK=
SW962 NW[5XndDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17JPGlEPTB;N{S4MlQ1KG6P MYDTRW5ITVJ?
MONO-MAC-6 NWDoOGpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrhbpcxUUN3ME23OVYvQTNibl2= NG\GXXpUSU6JRWK=
NCI-H748 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG2[IVKSzVyPUe1PE46QSCwTR?= NYPXbYliW0GQR1XS
NCI-H524 M4ezUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTd6MD63N{BvVQ>? M373UHNCVkeHUh?=
LS-123 NUjZW5lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHRTWM2OD15OUWuOlkhdk1? NYjMVWhKW0GQR1XS
NB7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRThzND6xOEBvVQ>? NU[5cW1QW0GQR1XS
LS-1034 NVzRRZQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTh{OD65PEBvVQ>? MYHTRW5ITVJ?
TE-5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXIfmtKSzVyPUi4N{42PiCwTR?= MmjYV2FPT0WU
A704 NGjGPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjnTWM2OD16OUmuNVUhdk1? MXLTRW5ITVJ?
TK10 NGXONmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfERZZCUUN3ME25NVYvODNibl2= NW\VWppoW0GQR1XS
NCI-H345 NIXlPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkftTWM2OD17NEOuNlIhdk1? M4PjSnNCVkeHUh?=
CGTH-W-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmriTWM2OD17NEiuNVMhdk1? MmTrV2FPT0WU
NCI-H510A NGrwR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zBS2lEPTB;OUi1MlEzKG6P M37k[3NCVkeHUh?=
NCI-H1963 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwMEOyPVIh|ryP MXPTRW5ITVJ?
SCC-3 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfLelFGUUN3ME2xMlA{PDF2IN88US=> MmD2V2FPT0WU
EW-11 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfaTWM2OD1zLkC4O|Q{KM7:TR?= MmfGV2FPT0WU
CPC-N MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLDdXNGUUN3ME2xMlA5QCEQvF2= M13sRnNCVkeHUh?=
NCI-H1417 NYPEWnRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwMUKyOkDPxE1? MWXTRW5ITVJ?
DG-75 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwMU[yPFUh|ryP MVzTRW5ITVJ?
HD-MY-Z MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwMU[0NVYh|ryP NYP3VFRnW0GQR1XS
ATN-1 M17xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPsV3FqUUN3ME2xMlI3OjB7IN88US=> MXPTRW5ITVJ?
KM-H2 M{\2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfOTWM2OD1zLkK2OFA5KM7:TR?= M1TUcXNCVkeHUh?=
NCI-H2081 NIHG[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLwTWM2OD1zLkK2OlM4KM7:TR?= MYHTRW5ITVJ?
HL-60 NW\iTZVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwMk[5OVkh|ryP MXHTRW5ITVJ?
DB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwMkeyOFIh|ryP MXnTRW5ITVJ?
NCI-H1522 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfVNXRPUUN3ME2xMlI5QDh5IN88US=> M3:0bXNCVkeHUh?=
AM-38 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorrTWM2OD1zLkOwO|Ih|ryP MX7TRW5ITVJ?
NCI-H446 Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7OcJl4UUN3ME2xMlMzOTJzIN88US=> NIDYXldUSU6JRWK=
SU-DHL-1 NXXCeG9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwM{K4NFEh|ryP MmPKV2FPT0WU
NH-12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwM{[zO|Qh|ryP MkXpV2FPT0WU
DMS-79 MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwM{[4OlYh|ryP MWjTRW5ITVJ?
NCI-H716 M{DERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\GTXhKSzVyPUGuN|g6QDZizszN NYXodoplW0GQR1XS
ML-2 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojuTWM2OD1zLkSxOVI6KM7:TR?= NHLsZ2xUSU6JRWK=
NB10 NIPuN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f5c2lEPTB;MT60OlY{OiEQvF2= MlnrV2FPT0WU
ONS-76 M1exO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSxTWM2OD1zLkWzOVY6KM7:TR?= M37qeHNCVkeHUh?=
LOUCY NYnleW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW0TWM2OD1zLkW0OlU4KM7:TR?= M2nNUXNCVkeHUh?=
SCLC-21H MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwNUi1PFIh|ryP M2HDZXNCVkeHUh?=
TGW M3TmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf0TWM2OD1zLk[zPVc2KM7:TR?= NXHDUJFTW0GQR1XS
LXF-289 NFT2N3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zGc2lEPTB;MT63N|I3QCEQvF2= M3\ldnNCVkeHUh?=
BB49-HNC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi3e3BKSzVyPUGuO|M2QDZizszN Mn7IV2FPT0WU
NCI-H747 M33OTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\kVVNKSzVyPUGuO|U{PDZizszN NYfZepJWW0GQR1XS
LU-165 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\6emc2UUN3ME2xMlg1QTh4IN88US=> MkjDV2FPT0WU
OMC-1 NUnZSmdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX0Z|RKSzVyPUGuPVUxPjZizszN NFnEdodUSU6JRWK=
RCC10RGB NFnhWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj4PHhKSzVyPUGuPVU5OTdizszN NGnW[mdUSU6JRWK=
SW684 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33IXmlEPTB;MT65OlA6QSEQvF2= NVr6[FN4W0GQR1XS
TE-8 M1LEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILiN4JKSzVyPUKuNFU2PTlizszN M2PKdXNCVkeHUh?=
SK-N-DZ NWTveoJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJwMUOyO|Qh|ryP M{HVT3NCVkeHUh?=
EVSA-T NEjndZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJwMUezNVUh|ryP NIK4NFlUSU6JRWK=
KASUMI-1 NXrwNYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\ucGZzUUN3ME2yMlE5QDF3IN88US=> NIfyd3BUSU6JRWK=
NKM-1 NHTqdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rpbWlEPTB;Mj6yOVQ4OiEQvF2= M{PpPXNCVkeHUh?=
CAL-148 NEe1WINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\TcmNKSzVyPUKuN|M3OTRizszN MmXRV2FPT0WU
NCI-H64 NEj1XpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\qdWlEPTB;Mj6zOFI{OiEQvF2= NX7IO3hzW0GQR1XS
KNS-81-FD NIjpdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjQOXFKSzVyPUKuN|Y3OiEQvF2= M1PaOnNCVkeHUh?=
KM12 M4nRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTtW5N5UUN3ME2yMlQxQDN7IN88US=> M1vM[XNCVkeHUh?=
SW954 M3jNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJwNEe3O|kh|ryP MkLCV2FPT0WU
NCI-H1395 M{Xhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXieHVKSzVyPUKuOVI3PDVizszN M4nMNHNCVkeHUh?=
DJM-1 NEjPU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;wWJNWUUN3ME2yMlYxPjNizszN MYHTRW5ITVJ?
COLO-668 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJwOEK2PVUh|ryP NEnmcWxUSU6JRWK=
NCI-H1436 Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrSVlFKSzVyPUKuPFU3OTVizszN MV;TRW5ITVJ?
LB2241-RCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrTNngyUUN3ME2yMlg3QDN7IN88US=> MoH1V2FPT0WU
GT3TKB M{DUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJwOEmwOVUh|ryP NX7uZpZRW0GQR1XS
COLO-824 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwOEm3Olgh|ryP M{ToRXNCVkeHUh?=
ES1 NEjIZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwOEm4O|kh|ryP NVXvfm9kW0GQR1XS
LB771-HNC NHjhNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXIW5RKSzVyPUKuPVA6PDZizszN M3fyfnNCVkeHUh?=
GI-ME-N NIO4N|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXixXZhmUUN3ME2zMlAxQTB2IN88US=> MmnFV2FPT0WU
NALM-6 NX3XT2NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rmcGlEPTB;Mz6wNFk{OyEQvF2= MYjTRW5ITVJ?
LU-134-A NGHLR|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHNWoE4UUN3ME2zMlA2PDJ3IN88US=> MV;TRW5ITVJ?
DMS-153 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqyXItKSzVyPUOuNFU5OjRizszN NY\OdFRTW0GQR1XS
MZ1-PC M4j6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3UT5dKSzVyPUOuNFkxPzhizszN NV3hbYhXW0GQR1XS
NCI-H1155 NGXvUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\2T4Z6UUN3ME2zMlEyPjFizszN NUfsO4RQW0GQR1XS
CAS-1 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTNwMUO3NFch|ryP NULBW5NtW0GQR1XS
D-502MG M{\RWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f6fGlEPTB;Mz6xOFM6KM7:TR?= NUnBXpNUW0GQR1XS
NCI-H2141 NFK4VGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTNwMUe0OVIh|ryP NHe0c|VUSU6JRWK=
NB6 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvBTWM2OD1|LkG4NlU6KM7:TR?= NWnITZc{W0GQR1XS
NCCIT NELXdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHpPYJqUUN3ME2zMlIyQDB7IN88US=> NWLVfI1tW0GQR1XS
NB69 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\yTWM2OD1|LkOxPFkyKM7:TR?= NVexT2dZW0GQR1XS
JVM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNwM{[0N|Mh|ryP MmPnV2FPT0WU
K052 MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzSXJRQUUN3ME2zMlM4QTZ6IN88US=> NWfjVGRqW0GQR1XS
HCC2157 NWrybZZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPoNpFjUUN3ME2zMlU{OjJ6IN88US=> Ml3KV2FPT0WU
KMOE-2 M4X0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLyTpFKSzVyPUOuOVQzPDJizszN MVHTRW5ITVJ?
SF268 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;GOYpKUUN3ME2zMlcyPTV2IN88US=> NHXSNpVUSU6JRWK=
CHP-126 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTO[21ZUUN3ME2zMlc3PDV6IN88US=> MX7TRW5ITVJ?
CP66-MEL NVrY[ohMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPGWXV6UUN3ME2zMlc6ODl2IN88US=> MlrFV2FPT0WU
NCI-H69 M{Hw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvZelhzUUN3ME20MlAyQTN4IN88US=> MXXTRW5ITVJ?
A253 NGrhWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfBNYNKSzVyPUSuNFIyODFizszN M1;FdnNCVkeHUh?=
NB14 NGfqfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT0TWM2OD12LkGwOFc6KM7:TR?= NGHH[HVUSU6JRWK=
NCI-H1694 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwMUOxNVIh|ryP M1XHOHNCVkeHUh?=
NCI-H2196 NHjvZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwMUexOlkh|ryP NVvjS5d4W0GQR1XS
TE-9 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jCVWlEPTB;ND6xO|U5OiEQvF2= NXKyRYdNW0GQR1XS
D-283MED MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrGUJdKSzVyPUSuNVg5PCEQvF2= NXHpUlg{W0GQR1XS
OCI-AML2 NYfzWY1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUmzZZF6UUN3ME20MlE6PDh7IN88US=> M4fuS3NCVkeHUh?=
D-263MG M{j6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C5PGlEPTB;ND6yNlk3OSEQvF2= M1y2OXNCVkeHUh?=
MPP-89 NIjpVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi4XZpKSzVyPUSuNlc{ODRizszN M3LSS3NCVkeHUh?=
LAMA-84 NVr4emdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rwPWlEPTB;ND6zNFQzOSEQvF2= NVrNRXpXW0GQR1XS
LB373-MEL-D M3n4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i1[mlEPTB;ND6zOlc5QSEQvF2= MW\TRW5ITVJ?
UACC-257 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXIfVVDUUN3ME20MlM6PTN2IN88US=> NYHDU443W0GQR1XS
MC-CAR M2PpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDWTWM2OD12LkSzPVkh|ryP M{fH[3NCVkeHUh?=
COLO-320-HSR M1TBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTRwNES0Nlch|ryP MVfTRW5ITVJ?
P30-OHK M1PGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\Ic|ZKSzVyPUSuOlY2QDFizszN M1\MeXNCVkeHUh?=
UACC-812 NGTrUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Oe49KSzVyPUSuOlkyPjFizszN MXjTRW5ITVJ?
CTB-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTRwN{G1OVUh|ryP MV7TRW5ITVJ?
ALL-PO NHjYNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjESXEzUUN3ME20Mlg1ODd5IN88US=> NFjRXFBUSU6JRWK=
SK-MEL-2 MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf1OINKSzVyPUSuPFY6PTVizszN M3S4PXNCVkeHUh?=
TC-YIK NYHqSFJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvDSJNKSzVyPUSuPVc6PDJizszN MVHTRW5ITVJ?
NCI-H1882 NGK3cYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorvTWM2OD13LkCyNFAyKM7:TR?= MY\TRW5ITVJ?
MHH-CALL-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[5TWM2OD13LkC1NFQzKM7:TR?= MV\TRW5ITVJ?
U-87-MG NFrPR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rrVWlEPTB;NT6wPVQ3PiEQvF2= MXHTRW5ITVJ?
NCI-H1092 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jT[mlEPTB;NT6yOlU2PSEQvF2= MUPTRW5ITVJ?
TE-441-T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofwTWM2OD13LkK3PFIh|ryP NYjVR|dYW0GQR1XS
SK-MEL-1 NEnxU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTVwMkmwOFQh|ryP NIjoW4hUSU6JRWK=
EW-22 NF\SO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v6[2lEPTB;NT6yPVQ3PiEQvF2= M2HOXnNCVkeHUh?=
MZ7-mel NHvON25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV20eml1UUN3ME21MlQxPjlzIN88US=> MXzTRW5ITVJ?
LP-1 M{jNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi0TWM2OD13LkSxNlkyKM7:TR?= M1nRfnNCVkeHUh?=
NCI-SNU-16 NGPBboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v2V2lEPTB;NT62OFA4PCEQvF2= NU\FS4R4W0GQR1XS
LU-65 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfvSIVJUUN3ME21Mlc3Ozd|IN88US=> MWPTRW5ITVJ?
CW-2 Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTVwOEW5OVkh|ryP MnLmV2FPT0WU
WSU-NHL NFnrd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTVwOUWxO|Qh|ryP MULTRW5ITVJ?
IST-MES1 NF;ZZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DYOGlEPTB;NT65OVQ1OyEQvF2= MXTTRW5ITVJ?
U-266 NXfoV3JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PPXGlEPTB;NT65PFIxOiEQvF2= MlHTV2FPT0WU
TALL-1 MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDLU3p3UUN3ME22MlE1Pjh6IN88US=> NGXkZWdUSU6JRWK=
Calu-6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HPXmlEPTB;Nj6xOVMyPiEQvF2= NEj0UHZUSU6JRWK=
MMAC-SF Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4KwU2lEPTB;Nj6xPFU2PiEQvF2= MnfMV2FPT0WU
NCI-H82 NUDM[WZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDSPGl3UUN3ME22MlIxPDh7IN88US=> NWrpO3I3W0GQR1XS
RS4-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTZwMkW4PVch|ryP NFXPZ|hUSU6JRWK=
SNU-C2B NXrt[3JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLOd|hKSzVyPU[uOFA6PjlizszN NFnpXmxUSU6JRWK=
BOKU NUjMe4k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL3dmlvUUN3ME22MlQ4PTl5IN88US=> MmXTV2FPT0WU
C8166 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLlU2RuUUN3ME22MlU2QTF{IN88US=> MWjTRW5ITVJ?
D-247MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTdwMESzOFch|ryP NX\QcJJ2W0GQR1XS
EW-18 M2TjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTdwMEeyPVIh|ryP MWjTRW5ITVJ?
KG-1 NXHEPHpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTdwNkK3N|gh|ryP MkDKV2FPT0WU
REH NUPQd2xJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7GNWFKSzVyPUeuOlgyODlizszN NGXyTnBUSU6JRWK=
U-698-M MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLVTWM2OD15Lki0N|E2KM7:TR?= MXrTRW5ITVJ?
KP-N-RT-BM-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEeybplKSzVyPUeuPVMxOjlizszN NX[xO2QyW0GQR1XS
MS-1 NIP6XXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;NUYFuUUN3ME23Mlk3ODRzIN88US=> NH6zRYRUSU6JRWK=
SNU-C1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TRc2lEPTB;Nz65PFE6OiEQvF2= NYTmdot[W0GQR1XS
SK-MM-2 M1zKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf5SGlKSzVyPUiuNlYxPjVizszN NWrpXnVXW0GQR1XS
LAN-6 M1f1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT0TWM2OD16LkOwNFAyKM7:TR?= NF;JdI1USU6JRWK=
NEC8 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj0d|lKSzVyPUiuN|A3QTFizszN MVnTRW5ITVJ?
NCI-H1770 M4HhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr5b2hKSzVyPUiuN|gxODJizszN M2LRRXNCVkeHUh?=
D-336MG NInKS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRThwNECxNVYh|ryP NI\K[IdUSU6JRWK=
COLO-829 NH7IRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjzd5dLUUN3ME24MlQ5QDd7IN88US=> NV7lVIdUW0GQR1XS
LS-513 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfDTWM2OD16LkW5OVk6KM7:TR?= M13lfXNCVkeHUh?=
YT MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRThwNkK0Nlch|ryP M4XoTHNCVkeHUh?=
EW-24 NXKwe5d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;vXGZKSzVyPUiuO|Y2PCEQvF2= MXzTRW5ITVJ?
IST-SL1 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq4doFKSzVyPUiuPFY2PDNizszN NWXjPXp6W0GQR1XS
CA46 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRThwOUWwPVgh|ryP NHHYTGFUSU6JRWK=
NCI-H1838 M4HDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nENmlEPTB;OD65PFYxOiEQvF2= Mmr4V2FPT0WU
NCI-H719 M{LoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jTfWlEPTB;OT6yOVI4QSEQvF2= NIDYWWJUSU6JRWK=
HCE-T NU\pc2Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nqWGlEPTB;OT6zNFg2OSEQvF2= NGTmbVFUSU6JRWK=
A498 NYLsdnZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTlwM{[xNlQh|ryP NFnET4VUSU6JRWK=
LB831-BLC NGLDToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HBT2lEPTB;OT63OlUzOSEQvF2= MWDTRW5ITVJ?
SKM-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTlwOEW5OlMh|ryP MYLTRW5ITVJ?
THP-1 NEfjVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXCTWM2OD17Lkm2PVE5KM7:TR?= NEfmdpBUSU6JRWK=
SHP-77 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFyLkSwO{DPxE1? NVOxVoc4W0GQR1XS
EW-3 M1rTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX61OIlSUUN3ME2xNE43Ojh7IN88US=> NGr6eHdUSU6JRWK=
KY821 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrDNpJKSzVyPUGwMlc3OyEQvF2= MV7TRW5ITVJ?
NCI-SNU-1 M1PjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HocWlEPTB;MUGuNFIyPyEQvF2= MULTRW5ITVJ?
HCC2218 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT6TWM2OD1zMT6zPVg3KM7:TR?= NEGyRYhUSU6JRWK=
IM-9 NHGwblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfY[nJYUUN3ME2xNU42OTB4IN88US=> NVrSZVBPW0GQR1XS
NCI-H889 NUPsZY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFzLkWzNVMh|ryP M4XGbXNCVkeHUh?=
HDLM-2 NVjQNGRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jye2lEPTB;MUKuOFE2QSEQvF2= NFPBWoNUSU6JRWK=
LB2518-MEL NEPtUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\3TWM2OD1zMj62PFE2KM7:TR?= NVzVTWhuW0GQR1XS
NCI-H23 M{iySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPIUJNKSzVyPUGzMlI1OjVizszN M3XhWXNCVkeHUh?=
NB17 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF|LkS1O|kh|ryP M1fuSXNCVkeHUh?=
NCI-H322M MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HiUWlEPTB;MUSuOFA3QCEQvF2= MV\TRW5ITVJ?
SUP-T1 MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Tnb2lEPTB;MUSuOFE{KM7:TR?= NGTj[pdUSU6JRWK=
ES3 NXXhRZdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnkdnVKSzVyPUG1MlA4ODNizszN MVPTRW5ITVJ?
ES5 NYfSb4cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7SUmtKSzVyPUG1MlA4QDdizszN NX\KcpRRW0GQR1XS
NCI-H1650 NHr1eXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPycndSUUN3ME2xOU41QTd7IN88US=> NUnMN5dQW0GQR1XS
NCI-H226 MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF3Lki3Olgh|ryP MXTTRW5ITVJ?
COR-L88 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jYbWlEPTB;MU[uN|E1KM7:TR?= M3rQSHNCVkeHUh?=
SCC-15 M2LYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XXVWlEPTB;MU[uN|g3QSEQvF2= NH\JO2xUSU6JRWK=
GOTO Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHxc2pQUUN3ME2xOk41Pzl|IN88US=> MkXjV2FPT0WU
SIMA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGyb21KSzVyPUG2MlQ5ODJizszN MVrTRW5ITVJ?
NCI-H1299 NEHhTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjGZoZyUUN3ME2xO{4yPTlzIN88US=> MVfTRW5ITVJ?
NCI-H1581 M1LSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnydmJxUUN3ME2xO{41OjF7IN88US=> NVfte3JDW0GQR1XS
MHH-NB-11 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvEellKSzVyPUG3Mlk3QDNizszN NUDtUGdsW0GQR1XS
MFM-223 NXHGT2g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\2N5NSUUN3ME2xPE4xPTN6IN88US=> NVHrTWIyW0GQR1XS
ES7 M1zaU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF6LkW0N|Eh|ryP MV7TRW5ITVJ?
JVM-3 MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[2TWM2OD1zOD63NVch|ryP M1yzbXNCVkeHUh?=
RL M3n0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn2NWRmUUN3ME2yNE4{QDhizszN M2\vfHNCVkeHUh?=
EC-GI-10 NF;M[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPXd29KSzVyPUKxMlIxPDFizszN MYnTRW5ITVJ?
LNCaP-Clone-FGC MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj3TWM2OD1{MT62O|Y5KM7:TR?= MWTTRW5ITVJ?
IMR-5 NXr2R45TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJzLki0PVQh|ryP NFG4UINUSU6JRWK=
KP-N-YS NV2xSHNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPkbGVCUUN3ME2yNU45PzVizszN NETsb2FUSU6JRWK=
Mo-T NW\acnFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\ue|VTUUN3ME2yNk4zOTh3IN88US=> MYXTRW5ITVJ?
NCI-H128 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jPNmlEPTB;MkOuOVg2OyEQvF2= NYnuWYJtW0GQR1XS
RH-1 NVv1[nAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Pq[2lEPTB;MkOuO|g3PiEQvF2= MWjTRW5ITVJ?
NCI-H2171 NFO0cW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITDNGtKSzVyPUK0MlI1QDVizszN NVrtc|BjW0GQR1XS
RPMI-8866 NUjq[YJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ4Lke0NkDPxE1? NI\0bJRUSU6JRWK=
SK-N-FI MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ5LkO4NVEh|ryP M4\JbnNCVkeHUh?=
LOXIMVI MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ5LkiwOVEh|ryP Mof3V2FPT0WU
P31-FUJ NHf3OIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITMUFFKSzVyPUOxMlU{PzRizszN NFLCRZhUSU6JRWK=
KMS-12-PE NHHsZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33jNmlEPTB;NEmuOVMxOiEQvF2= NUfQ[WhnW0GQR1XS

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
in solvent
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

mTOR信号経路図

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID